Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.

Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.

PMID:
31227646
2.

Tramadol hydrochloride 75 mg/dexketoprofen 25 mg oral fixed-dose combination in moderate-to-severe acute pain: sustained analgesic effect over a 56-h period in the postoperative setting.

Montero Matamala A, Bertolotti M, Contini MP, Guerrero Bayón C, Nizzardo A, Paredes Lario I, Pizà Vallespir B, Scartoni S, Tonini G, Capriati A, Pellacani A.

Drugs Today (Barc). 2017 Jun;53(6):339-347. doi: 10.1358/dot.2017.53.6.2636487. Review.

PMID:
28799579
3.

1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.

Micheli F, Bacchi A, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Dal Cin M, Feriani A, Gehanne S, Kajbaf M, Marchió L, Nola S, Oliosi B, Pellacani A, Perdonà E, Sava A, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C.

J Med Chem. 2016 Sep 22;59(18):8549-76. doi: 10.1021/acs.jmedchem.6b00972. Epub 2016 Sep 9.

PMID:
27564135
4.

AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes.

Katz L, Manamley N, Snyder WJ, Dodds M, Agafonova N, Sierra-Johnson J, Cruz M, Kaur P, Mudaliar S, Raskin P, Kewalramani R, Pellacani A.

Diabetes Obes Metab. 2016 Feb;18(2):191-5. doi: 10.1111/dom.12586. Epub 2015 Dec 14.

PMID:
26434934
5.

Molecular targeting of the GK-GKRP pathway in diabetes.

Hale C, Lloyd DJ, Pellacani A, Véniant MM.

Expert Opin Ther Targets. 2015 Jan;19(1):129-39. doi: 10.1517/14728222.2014.965681. Epub 2014 Oct 17. Review.

PMID:
25324018
6.

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.

Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.

Int J Biol Sci. 2012;8(3):310-27. doi: 10.7150/ijbs.3524. Epub 2012 Feb 9.

7.

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, Stasi L, Spada S, Stemp G, Nash D, Branch C, Kindon L, Massagrande M, Poffe A, Braggio S, Chiarparin E, Marchioro C, Ratti E, Corsi M.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5562-7. doi: 10.1016/j.bmcl.2011.06.086. Epub 2011 Jun 30.

PMID:
21831639
8.

2-Methyl-3-furanyl-4H-1,2,4-triazol-3-ylthioamides: a new class of selective orexin 2 antagonists.

Micheli F, Antolini M, Di Fabio R, Pellacani A, Pozzan A.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6405-7. doi: 10.1016/j.bmcl.2010.09.090. Epub 2010 Sep 19.

PMID:
20933413
9.

Is wear debris responsible for failure in alumina-on-alumina implants?

Savarino L, Baldini N, Ciapetti G, Pellacani A, Giunti A.

Acta Orthop. 2009 Apr;80(2):162-7. doi: 10.3109/17453670902876730.

10.

Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.

Granchi D, Pellacani A, Spina M, Cenni E, Savarino LM, Baldini N, Giunti A.

J Bone Joint Surg Am. 2006 Jul;88(7):1501-9.

PMID:
16818976
11.

Height as a risk factor for osteosarcoma.

Longhi A, Pasini A, Cicognani A, Baronio F, Pellacani A, Baldini N, Bacci G.

J Pediatr Hematol Oncol. 2005 Jun;27(6):314-8.

PMID:
15956884
12.

Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses.

Cenni E, Savarino L, Antonioli D, Pellacani A, Giunti A, Baldini N.

Acta Orthop. 2005 Feb;76(1):61-6.

PMID:
15788309
13.

Deep peroneal nerve paresis in a runner caused by ganglion at capitulum peronei. Case report and review of the literature.

Dallari D, Pellacani A, Marinelli A, Verni E, Giunti A.

J Sports Med Phys Fitness. 2004 Dec;44(4):436-40. Review.

PMID:
15758858
14.

In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells.

Granchi D, Amato I, Battistelli L, Avnet S, Capaccioli S, Papucci L, Donnini M, Pellacani A, Brandi ML, Giunti A, Baldini N.

Int J Cancer. 2004 Oct 10;111(6):829-38.

15.

Diagnosis of infection after total hip replacement.

Savarino L, Baldini N, Tarabusi C, Pellacani A, Giunti A.

J Biomed Mater Res B Appl Biomater. 2004 Jul 15;70(1):139-45.

PMID:
15199594
16.

The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation.

Granchi D, Ciapetti G, Amato I, Pagani S, Cenni E, Savarino L, Avnet S, Peris JL, Pellacani A, Baldini N, Giunti A.

Biomaterials. 2004 Aug;25(18):4037-45.

PMID:
15046894
17.

Osteoid osteoma simulating an osteocartilaginous exostosis.

Marinelli A, Giacomini S, Bianchi G, Pellacani A, Bertoni F, Mercuri M.

Skeletal Radiol. 2004 Mar;33(3):181-5. Epub 2004 Jan 23.

PMID:
14740185
18.

The antidepressant fluoxetine blocks the human small conductance calcium-activated potassium channels SK1, SK2 and SK3.

Terstappen GC, Pellacani A, Aldegheri L, Graziani F, Carignani C, Pula G, Virginio C.

Neurosci Lett. 2003 Jul 31;346(1-2):85-8.

PMID:
12850554
19.

Xanthoma of bone: first sign of hyperlipidemia type IIB: a case report.

Dallari D, Marinelli A, Pellacani A, Valeriani L, Lesi C, Bertoni F, Giunti A.

Clin Orthop Relat Res. 2003 May;(410):274-7.

PMID:
12771840
20.

Mucous cysts of bone communicating with the joint cavity.

Rimondi E, Dallari D, Marinelli A, Pellacani A.

Radiol Med. 2002 Mar;103(3):282-5. English, Italian. No abstract available.

PMID:
11976628
21.

Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice.

Layne MD, Patel A, Chen YH, Rebel VI, Carvajal IM, Pellacani A, Ith B, Zhao D, Schreiber BM, Yet SF, Lee ME, Storch J, Perrella MA.

FASEB J. 2001 Dec;15(14):2733-5. Epub 2001 Oct 15.

PMID:
11606480
22.

Absence of adipocyte fatty acid binding protein prevents the development of accelerated atherosclerosis in hypercholesterolemic mice.

Perrella MA, Pellacani A, Layne MD, Patel A, Zhao D, Schreiber BM, Storch J, Feinberg MW, Hsieh CM, Haber E, Lee ME.

FASEB J. 2001 Aug;15(10):1774-6. No abstract available.

PMID:
11481226
23.

Exacerbation of chronic renovascular hypertension and acute renal failure in heme oxygenase-1-deficient mice.

Wiesel P, Patel AP, Carvajal IM, Wang ZY, Pellacani A, Maemura K, DiFonzo N, Rennke HG, Layne MD, Yet SF, Lee ME, Perrella MA.

Circ Res. 2001 May 25;88(10):1088-94.

PMID:
11375280
24.

Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric-oxide synthase 2 by transforming growth factor-beta1.

Pellacani A, Wiesel P, Razavi S, Vasilj V, Feinberg MW, Chin MT, Reeves R, Perrella MA.

J Biol Chem. 2001 Jan 12;276(2):1653-9.

25.

ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-kappa B to regulate the inducible nitric-oxide synthase gene.

Rudders S, Gaspar J, Madore R, Voland C, Grall F, Patel A, Pellacani A, Perrella MA, Libermann TA, Oettgen P.

J Biol Chem. 2001 Feb 2;276(5):3302-9. Epub 2000 Oct 17.

26.

Transforming growth factor-beta 1 inhibition of macrophage activation is mediated via Smad3.

Werner F, Jain MK, Feinberg MW, Sibinga NE, Pellacani A, Wiesel P, Chin MT, Topper JN, Perrella MA, Lee ME.

J Biol Chem. 2000 Nov 24;275(47):36653-8.

27.

Thioredoxin facilitates the induction of heme oxygenase-1 in response to inflammatory mediators.

Wiesel P, Foster LC, Pellacani A, Layne MD, Hsieh CM, Huggins GS, Strauss P, Yet SF, Perrella MA.

J Biol Chem. 2000 Aug 11;275(32):24840-6.

28.

Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells.

Foster LC, Wiesel P, Huggins GS, Pañares R, Chin MT, Pellacani A, Perrella MA.

FASEB J. 2000 Feb;14(2):368-78.

PMID:
10657993
29.

Induction of high mobility group I architectural transcription factors in proliferating vascular smooth muscle in vivo and in vitro.

Chin MT, Pellacani A, Hsieh CM, Lin SS, Jain MK, Patel A, Huggins GS, Reeves R, Perrella MA, Lee ME.

J Mol Cell Cardiol. 1999 Dec;31(12):2199-205.

PMID:
10640447
30.

Endotoxin-induced mortality is related to increased oxidative stress and end-organ dysfunction, not refractory hypotension, in heme oxygenase-1-deficient mice.

Wiesel P, Patel AP, DiFonzo N, Marria PB, Sim CU, Pellacani A, Maemura K, LeBlanc BW, Marino K, Doerschuk CM, Yet SF, Lee ME, Perrella MA.

Circulation. 2000 Dec 12;102(24):3015-22.

PMID:
11113055
31.

Acute methylprednisolone administration induces a transient alteration of glucose tolerance and pyruvate dehydrogenase in humans.

Pellacani A, Fornengo P, Bruno A, Ceruti C, Mioletti S, Curto M, Rinaudo MT, Pagano G, Cavallo-Perin P.

Eur J Clin Invest. 1999 Oct;29(10):861-7.

PMID:
10583428
32.

All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines.

Visani G, Ottaviani E, Zauli G, Tosi P, Pellacani A, Isidori A, Pierpaoli S, Tura S.

Eur J Haematol. 1999 Sep;63(3):149-53.

PMID:
10485269
33.

In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.

Tosi P, Pellacani A, Zinzani PL, Magagnoli M, Visani G, Tura S.

Haematologica. 1999 Sep;84(9):794-8.

34.

Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.

Pellacani A, Tosi P, Zinzani PL, Ottaviani E, Albertini P, Magagnoli M, Tura S.

Leuk Lymphoma. 1999 Mar;33(1-2):147-53.

PMID:
10194132
35.

In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells.

Tosi P, Pellacani A, Visani G, Ottaviani E, Ronconi S, Zamagni E, Benni M, Cavo M, Tura S.

Eur J Haematol. 1999 Mar;62(3):143-8.

PMID:
10089890
36.

High mobility group-I(Y) protein facilitates nuclear factor-kappaB binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer.

Perrella MA, Pellacani A, Wiesel P, Chin MT, Foster LC, Ibanez M, Hsieh CM, Reeves R, Yet SF, Lee ME.

J Biol Chem. 1999 Mar 26;274(13):9045-52.

37.

Induction of high mobility group-I(Y) protein by endotoxin and interleukin-1beta in vascular smooth muscle cells. Role in activation of inducible nitric oxide synthase.

Pellacani A, Chin MT, Wiesel P, Ibanez M, Patel A, Yet SF, Hsieh CM, Paulauskis JD, Reeves R, Lee ME, Perrella MA.

J Biol Chem. 1999 Jan 15;274(3):1525-32.

38.

Plasma bradykinin in angio-oedema.

Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A.

Lancet. 1998 Jun 6;351(9117):1693-7.

PMID:
9734886
39.

Induction of heme oxygenase-1 during endotoxemia is downregulated by transforming growth factor-beta1.

Pellacani A, Wiesel P, Sharma A, Foster LC, Huggins GS, Yet SF, Perrella MA.

Circ Res. 1998 Aug 24;83(4):396-403.

PMID:
9721696
40.

Enhancement of serum-response factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y).

Chin MT, Pellacani A, Wang H, Lin SS, Jain MK, Perrella MA, Lee ME.

J Biol Chem. 1998 Apr 17;273(16):9755-60.

41.

Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.

Tosi P, Visani G, Ottaviani E, Testoni N, Pellacani A, Tura S.

Eur J Haematol. 1998 Mar;60(3):161-5.

PMID:
9548414
42.

Reduction of heat-shock protein-70 after prolonged treatment with retinoids: biological and clinical implications.

Tosi P, Visani G, Ottaviani E, Gibellini D, Pellacani A, Tura S.

Am J Hematol. 1997 Nov;56(3):143-50.

43.

Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.

Tosi P, Zinzani PL, Pellacani A, Ottaviani E, Magagnoli M, Tura S.

Leuk Lymphoma. 1997 Jul;26(3-4):343-8.

PMID:
9322897
44.
45.

Induction of heme oxygenase-1 expression in vascular smooth muscle cells. A link to endotoxic shock.

Yet SF, Pellacani A, Patterson C, Tan L, Folta SC, Foster L, Lee WS, Hsieh CM, Perrella MA.

J Biol Chem. 1997 Feb 14;272(7):4295-301.

46.

Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines.

Tosi P, Visani G, Ottaviani E, Pellacani A, Manfroi S, Tura S.

Anticancer Drugs. 1996 Sep;7(7):774-9.

PMID:
8949989
47.

Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects.

Pellacani A, Brunner HR, Nussberger J.

Clin Sci (Lond). 1994 Nov;87(5):567-74.

PMID:
7874846
48.

[Familial Mediterranean fever: a report of 2 cases of Italian origin].

Marinone C, Bisbocci D, Pellacani A, Chiandussi L.

Ann Ital Med Int. 1992 Apr-Jun;7(2):114-7. Italian.

PMID:
1467126
49.

Antagonizing and measurement: approaches to understanding of hemodynamic effects of kinins.

Pellacani A, Brunner HR, Nussberger J.

J Cardiovasc Pharmacol. 1992;20 Suppl 9:S28-34. Review.

PMID:
1282626
50.

Association of the Budd-Chiari syndrome with lupus anticoagulant. Case report and critical review.

Bisbocci D, De Micheli AG, Tamanti P, Cantoni R, Pellacani A, Pinna G, Marinone C, Chiandussi L.

Ann Ital Med Int. 1991 Apr-Jun;6(2):251-5.

PMID:
1747329

Supplemental Content

Loading ...
Support Center